Marizyme (Marizyme) Change In Receivables : $0.08 Mil (TTM As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Marizyme Change In Receivables?

Marizyme's change in receivables for the quarter that ended in Mar. 2024 was $0.06 Mil. It means Marizyme's Accounts Receivable declined by $0.06 Mil from Dec. 2023 to Mar. 2024 .

Marizyme's change in receivables for the fiscal year that ended in Dec. 2023 was $0.01 Mil. It means Marizyme's Accounts Receivable declined by $0.01 Mil from Dec. 2022 to Dec. 2023 .

Marizyme's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Marizyme's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Marizyme's liquidation value for the three months ended in Mar. 2024 was $-32.39 Mil.

Marizyme Change In Receivables Historical Data

The historical data trend for Marizyme's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marizyme Change In Receivables Chart

Marizyme Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.04

0.04

-0.05

0.01

Marizyme Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.01	0.01	0.03	-0.02	0.06

Marizyme Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.

Marizyme (OTCPK:MRZM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Marizyme's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.033	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Marizyme's accounts receivable are only considered to be worth 75% of book value:

Marizyme's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.006	-	32.403	+	0.75 * 0	+	0.5 * 0.015
=	-32.39

Marizyme Change In Receivables Related Terms

Thank you for viewing the detailed overview of Marizyme's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Marizyme (Marizyme) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marizyme Inc (OTCPK:MRZM) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458

Website

https://www.marizyme.com

Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.

Executives

Braeden Lichti	10 percent owner	650 GEORGIA ST #3200, VANCOUVER A1 V6B4P7
Nilesh Umedbhai Patel	director	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Michael R Stewart	director	5 WALNUT GROVE DRIVE, STE 140, HORSHAM PA 19044
Harrison Ross	officer: Vice President of Finance	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Georgiy Kovalyov	officer: Chief Financial Officer	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
David Barthel	director, officer: Chief Executive Officer	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Bradley Richmond	officer: Acting VP of Finance	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Julie B. Kampf	director	14054 OLD CYPRESS BEND, PALM BEACH GARDENS FL 33410
Vithalbhai D Dhaduk	director	FNCB BANCORP, INC., 102 E. DRINKER ST., DUNMORE PA 18512
Neil J Campbell	director, officer: Chief Executive Officer	225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Very Donald Leroy Jr	officer: Executive Vice President	4 SILVERWHITE AVENUE, LITTLE SILVER NJ 07739
William Hearl	director	448 SALK CIRCLE, GAITHERSBERG MD 20878
Bruce Harmon	officer: Chief Financial Officer	316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Catherine J. Pachuk	officer: Chief Science Officer	1033 N. JEAGA DR, JUPITER FL 33458
Satishchandran Chandrasekhar	officer: Chief Operating Officer	167 CARMELA COURT, JUPITER FL 33478